| Amgen-Bruce Wallace Program - Video Scientists Will Engage With Students Participating In The Amgen-Bruce Wallace Biotechnology Lab Program feedproxy.google.com |
His Honor's Fitness Secret: Treads and Risers In What's Your Workout?, Denver mayor John Hickenlooper encourages a "stairs only" approach to fitness for himself and municipal employees. online.wsj.com |
Forest Labs: Earnings Scorecard Zacks.com submits: Following the release of first quarter fiscal 2011 results on July 20, 2010, almost all the analysts covering Forest Laboratories (FRX) have made upward revisions to their earnings estimates for 2011 and 2012. The upward revision in estimates is mainly in response to the company’s revised guidance for fiscal 2011.First Quarter Highlights: Forest Labs reported first quarter earnings per share of 95 cents, well above the Zacks Consensus Estimate of 86 cents and the year-earlier earnings of 87 cents. Strong Namenda sales, lower SG&A expenses and lower share count boosted earnings.Complete Story » seekingalpha.com |
Keryx Remains a Focused, Well-Funded Bio-Pharma Play Mike Havrilla submits:Keryx Biopharmaceuticals, Inc. (NASDAQ: KERX) is an emerging, small-cap biopharma company that has a pair of lead compounds in late-stage, Phase 3 development for the treatment of cancer (perifosine) and renal disease (Zerenex) under Special Protocol Assessment (SPA) agreements with the FDA. I initially wrote about KERX in January 2010, and the Company has performed well (with stock price doubling from approx. $2.50 to $5.00 per share) thanks to delivering on its strategic objectives of advancing its lead compounds into three pivotal Phase 3 studies - with Phase 3 results expected for Zerenex in about three months (December timeframe). KERX is well capitalized with no debt/convertibles and approximately $32 million in cash/equivalents as of 6/30/10. In addition, the Company has about 59 million shares of common stock outstanding with a fully diluted share count of 70 million and average daily trading volume that has grown over the past year to over 1 million shares per day. The expected cash burn rate for KERX during 2H10 is approximately $10 million, which will be offset by the same amount in expected milestone payments over the next six months that include option/warrant exercises and a milestone payment from its Zerenex partner in Japan (JT Torii) upon initiation of a pivotal Phase 3 study.Complete Story » seekingalpha.com |
Sanofi / Genzyme Battle Likely to End Somewhere in the Middle Wall Street Cheat Sheet submits: By Joanna BromleyThis week we’ll discuss Sanofi-Aventis’ (SNY) potential acquisition of Genzyme (GENZ). Despite the dozens of news items in the past few months, the story remains essentially the same: Sanofi wants Genzyme, but at an unpalatable price. Unofficial, friendly merger talks began over the summer, but now the $18.5 billion bid has gone hostile.Complete Story » seekingalpha.com |